Stockscreener 앱 받기
123.54
1.22%
-1.53
시간 외 거래:
123.97
0.43
+0.35%
전일 마감가:
$125.07
열려 있는:
$125.12
하루 거래량:
8.20M
Relative Volume:
0.80
시가총액:
$305.12B
수익:
$65.51B
순이익/손실:
$8.93B
주가수익비율:
34.77
EPS:
3.5532
순현금흐름:
$14.12B
1주 성능:
-4.65%
1개월 성능:
+3.74%
6개월 성능:
+11.77%
1년 성능:
+47.04%
1일 변동 폭
$122.90
$125.56
1주일 범위
$122.90
$130.00
52주 변동 폭
$76.66
$130.29
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
123.54 | 308.90B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,188.58 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 623.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 441.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
154.05 | 295.03B | 54.66B | 13.58B | 16.05B | 7.0171 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-02-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-08 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-10-13 | 재개 | Citigroup | Neutral |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Merck (MRK) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Merck & Co. stock holds steady as a big pharma mainstay in the S&P 500 - ad-hoc-news.de
Merck & Co. stock holds steady as oncology and vaccines underpin long-term growth - AD HOC NEWS
symbol__ Stock Quote Price and Forecast - CNN
Merck & Co., Inc. (MRK) is attracting investor attention: Here is what you should know - MSN
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? - The Motley Fool
Merck & Co. Inc. updates its oncology pipeline as a major S&P 500 healthcare player - AD HOC NEWS
Merck & Co. focuses on oncology and vaccines as a major global pharma player - Ad-hoc-news.de
Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds - IPO Edge
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co. highlights oncology pipeline progress as S&P 500 healthcare heavyweight. Longer-term gro - Ad-hoc-news.de
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Merck & Co. focuses on oncology pipeline as investors watch long-term growth - Ad-hoc-news.de
Merck & Co. Inc. balances pharmaceuticals growth and pipeline investment - Ad-hoc-news.de
Merck & Co. highlights its pharmaceutical portfolio as investors track long-term growth prospects - AD HOC NEWS
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Merck & Co. highlights its pharmaceuticals strength as investors track long term growth - AD HOC NEWS
Merck & Co. highlights its pharmaceutical portfolio as a major global healthcare player - AD HOC NEWS
Merck & Co. looks to long-term growth as a global pharmaceutical leader - AD HOC NEWS
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co. focuses on oncology and vaccines as investors watch long-term growth - AD HOC NEWS
HSBC Adjusts Price Target on Merck & Co to $150 From $135 - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on Merck to $145 From $140 - Moomoo
Merck & Company, Inc. (MRK): Investor Outlook with a 2.62% Dividend Yield and Robust Buy Ratings - DirectorsTalk Interviews
Enterprise value to revenue forward of Merck & Co., Inc. – BX:6MK - TradingView
Redwood Grove Capital, LLC's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Te - GuruFocus
Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Merck & Co Inc Stock (MRK) Closed Up by 3.16% on Jul 2: What Signal Does It Send? - TradingKey
Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up (NYSE:MRK) - Seeking Alpha
MRKMerck & Co Inc Volatility & Greeks - Finviz
Merck & Co. focuses on long-term growth as a global healthcare leader - AD HOC NEWS
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - BioSpace
Merck & Co | 4: Statement of changes in beneficial ownership of securities-Director Seidman Christine E - Moomoo
Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says - Moomoo
Merck & Co earnings guidance frames 2026 outlook. Technicals show MRK trading in a tight range - AD HOC NEWS
Merck, AbbVie probed by US lawmakers over China clinical trials: report - Proactive financial news
Merck & Co. dividend track and pharma pipeline, shares in a mature Dow component - AD HOC NEWS
Merck (NYSE:MRK) Draws Heat As Healthcare Surges - Kalkine Media
Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh - TradingView
Merck expands HIV drug access through state AIDS programs - Stock Titan
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Business Wire
Merck & Company, Inc. (MRK) Stock Analysis: Evaluating Growth Prospects Amid a 1.35% Potential Upside - DirectorsTalk Interviews
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Merck & Co. highlights Keytruda momentum, pharma stock in long-term focus - AD HOC NEWS
The Keytruda from Merck & Co. Inc.lung cancer data extend its reach - AD HOC NEWS
Merck & Co., Inc.(NYSE: MRK) added to Russell 1000 Dynamic Index - marketscreener.com
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRK - The National Law Review
Merck & Co. updates on Keytruda data, shares anchored by strong oncology franchise - Ad-hoc-news.de
Merck & Co. opens the week with earnings focus, shares in New York - Ad-hoc-news.de
Lost Money on Merck & Co., Inc. (MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - The National Law Review
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
1.23%
자본화:
|
볼륨(24시간):